fluspirilene has been researched along with Diabetes Mellitus, Type 2 in 1 studies
Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Tabatabaei Dakhili, SA | 1 |
Greenwell, AA | 1 |
Yang, K | 1 |
Abou Farraj, R | 1 |
Saed, CT | 1 |
Gopal, K | 1 |
Chan, JSF | 1 |
Chahade, JJ | 1 |
Eaton, F | 1 |
Lee, C | 1 |
Velázquez-Martínez, CA | 1 |
Crawford, PA | 1 |
Glover, JNM | 1 |
Al Batran, R | 1 |
Ussher, JR | 1 |
1 other study available for fluspirilene and Diabetes Mellitus, Type 2
Article | Year |
---|---|
The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase.
Topics: Animals; Antipsychotic Agents; Coenzyme A-Transferases; Diabetes Mellitus, Type 2; Dopamine; Fluspir | 2023 |